

1 **Genetic determinants of intrinsic antibiotic tolerance in *Mycobacterium avium***

2 William M. Matern^{1,2,3}, Harley Parker^{2,3}, Carina Danchik^{2,3}, Leah Hoover^{2,3}, Joel S. Bader^{1,2}, Petros C.

3 Karakousis^{2,3,4,f}

4 1. High-Throughput Biology Center, Department of Biomedical Engineering, Johns Hopkins University

5 School of Medicine, Baltimore, MD

6 2. Center for Systems Approaches to Infectious Diseases (C-SAID), Johns Hopkins University School of

7 Medicine, Baltimore, MD

8 3. Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of

9 Medicine, Baltimore, MD

10 4. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore,

11 MD

12 *f* Corresponding author:

13 Koch Cancer Research (CRB-2) Building

14 1550 Orleans St., Room 110

15 Baltimore, MD 21287

16 petros@jhmi.edu

17 **Abstract**

18 *Mycobacterium avium* complex (MAC) is one of the most prevalent causes of nontuberculous
19 mycobacteria pulmonary infection in the United States, yet it remains understudied. Current MAC
20 treatment requires more than a year of intermittent to daily combination antibiotic therapy, depending on
21 disease severity. In order to shorten and simplify curative regimens, it is important to identify the innate
22 bacterial factors contributing to reduced antibiotic susceptibility, namely antibiotic tolerance genes. In this
23 study, we performed a genome-wide transposon screen to elucidate *M. avium* genes that play a role in the
24 bacterium's tolerance to first- and second-line antibiotics. We identified a total of 193 unique *M. avium*
25 mutants with significantly altered susceptibility to at least one of the four clinically used antibiotics we
26 tested, including two mutants (in DFS55_00905 and DFS55_12730) with panhypersusceptibility. The
27 products of the antibiotic tolerance genes we have identified may represent novel targets for future drug
28 development studies aimed at shortening the duration of therapy for MAC infections.

29 **Importance**

30 The prolonged treatment required to eradicate *Mycobacterium avium* complex (MAC) infection is
31 likely due to the presence of subpopulations of antibiotic-tolerant bacteria with reduced susceptibility to
32 currently available drugs. However, little is known about the genes and pathways responsible for
33 antibiotic tolerance in MAC. In this study, we performed a forward genetic screen to identify *M. avium*
34 antibiotic tolerance genes, whose products may represent attractive targets for the development of novel
35 adjunctive drugs capable of shortening curative treatment for MAC infections.

36

37 **Introduction**

38 Nontuberculous mycobacteria (NTM) are found ubiquitously in the environment and several species
39 can cause disease especially in the elderly, those with preexisting lung disease, and the
40 immunocompromised, including those infected with HIV (1–4). *Mycobacterium avium* complex (MAC),
41 a group of 12 related, slow-growing mycobacteria with *M. intracellulare* and *M. avium* as the most
42 prevalent species, accounts for the majority of pulmonary infections due to NTM in the US (5,6).
43 Although the true incidence of pulmonary MAC infections in the US is not known, a study in Oregon
44 reported 4.8 cases per 100,000 person-years in 2012 (7). Winthrop *et al.* estimated the annual incidence of
45 NTM infections in the US to be 4.73 cases per 100,000 person-years (8), and the NTM-NET group has
46 reported that MAC accounts for 52% of NTM isolates in the USA and Canada (9), suggesting the annual
47 incidence of MAC in the US may be closer to ~2.5 per 100,000 person-years in the US.

48 Current treatment for MAC comprises a combination of multiple antibiotics given for at least 12
49 months following the conversion of sputum cultures from positive to negative. Since sputum culture
50 conversion occurs in ~50% of cases after five months of antibiotic therapy, a typical patient receives a
51 minimum of 15-18 months of treatment (10,11). Macrolide-susceptible MAC is usually treated with at
52 least three antibiotics, including a macrolide (azithromycin or clarithromycin), a rifamycin (rifampin or
53 rifabutin), and ethambutol, either intermittently (three times weekly) or daily for severe fibronodular or
54 cavitary disease. If the infecting MAC strain is macrolide-resistant or the patient is unable to take the
55 first-line regimen, alternative antibiotics, such as moxifloxacin, clofazimine, or linezolid are often used
56 (11,12).

57 The lengthy and complicated treatment course required to eradicate MAC infection has been
58 attributed to the presence of persistent organisms, which exhibit reduced susceptibility, or tolerance, to
59 antibiotics (13). Unlike antibiotic resistance, which results from a heritable genetic alteration permitting
60 continued bacterial growth in the presence of antibiotic concentrations exceeding the minimum inhibitory

61 concentration (MIC), antibiotic tolerance is a transient, nonheritable phenotype without associated change
62 in the MIC. The term “antibiotic tolerance” was originally coined in 1970 by Tomasz *et al.* to denote the
63 ability of bacteria to withstand the bactericidal activity of antibiotics, especially of cell wall-active agents,
64 primarily by reducing their replication rate (14). In the intervening decades, additional mechanisms have
65 been proposed to mediate bacterial antibiotic tolerance, including biofilm formation (15,16), the stringent
66 response (17–20), induction of efflux pumps (21–23), and altered metabolism (24,25). Following
67 ingestion by macrophages, MAC acquires an antibiotic-tolerant phenotype within the arrested phagosome
68 (26). Moreover, various stress conditions, including nutrient starvation, low pH and hypoxia, induce a
69 nonreplicative, antibiotic-tolerant state (24), which is characterized by transcriptional changes (24,25),
70 leading to altered cell wall membrane permeability (3) and increased expression of efflux pumps (21).
71 This stress-induced adaptation of MAC is accompanied by dramatically reduced metabolism, with a shift
72 to the glyoxylate shunt, stabilization of the mycolate pool, and a switch to transcription of only essential
73 genes (25). Additionally, the glyoxylate shunt enzyme isocitrate lyase is critical for long-term survival of
74 the related pathogen *M. tuberculosis* in host tissues (27), and can be used in a reductive amination
75 pathway to produce NAD, which may serve as an alternative energy source in a nonreplicative state and
76 under anaerobic conditions (28,29). However, the molecular mechanisms driving antibiotic tolerance in
77 MAC remain poorly understood.

78 Transposon insertion sequencing (Tn-seq) is a powerful technique for determining bacterial
79 genotype-phenotype relationships, particularly the requirement for specific bacterial genes for growth
80 and/or survival under controlled stress conditions (30–33). Modifications of this technique have been
81 used to define essential genes for *in vitro* growth of *M. tuberculosis* (34) and *M. avium* (35). Xu *et al.*
82 screened a saturated transposon mutant library in the presence of partially inhibitory concentrations of
83 various antibiotics with diverse mechanisms of action to identify genetic determinants of intrinsic
84 antibiotic susceptibility in *M. tuberculosis* (36). In the current study, we used a similar approach to
85 identify genes responsible for intrinsic tolerance of *M. avium* to the antibiotics clarithromycin (CLR),

86 rifabutin (RFB), moxifloxacin (MOX), and ethambutol (EMB). The hits we have identified may serve as
87 targets for the development of novel antibiotics, with the objective of shortening the duration of curative
88 treatment for MAC.

89

90 **Methods**

91 **Strains**

92 All experiments were performed using *Mycobacterium avium* subsp. *hominissuis* strain 109 (35).

93

94 **Media and buffers**

95 To make 7H11 agar, 10.25 g of 7H11 w/o Malachite Green powder (HiMedia Cat No. 511A) was
96 added to 450 mL deionized water. A volume of 5 mL 50% glycerol was then added before autoclaving.

97 The agar was cooled to 55° C before addition of 50 mL OADC enrichment (Becton Dickinson). To make
98 7H9/30% OADC, 2.35 g of 7H9 powder was added to 350 mL deionized water. After sterilization (by
99 autoclaving at 121° C or passing through a 0.22 µm filter) 150 mL of OADC enrichment was added.

100 Unless otherwise specified, no Tween-80 or glycerol was included in the media. To make PBS-Tw,
101 1.25mL filter-sterilized 20% Tween-80 was added to 500 mL of sterile phosphate-buffered saline (PBS).

102

103 **Overview of transposon screen setup**

104 The setup for our genome-wide differential susceptibility screen is shown in Figure 1. We
105 inoculated a 1-mL frozen aliquot of a previously generated diverse *HimarI* transposon mutant pool
106 (consisting of approximately 1.2×10^6 unique mutants) (35) into 300 mL of 7H9/30% OADC contained
107 in a 1.3-L roller bottle. This was shaken at 37°C for 24 hours to reduce bacterial clumping (220 rpm, 0.75

108 in [1.905 cm] orbit). The optical density at 600 nm (OD_{600}) was tracked until exceeding 0.32. The
109 transposon mutants were then diluted to OD_{600} 0.1 with cold 7H9/30% OADC and aliquoted into 89 50-
110 mL conical tubes (10 mL/tube). Tubes were incubated for 5 hours while shaking at 37° C to allow the
111 bacteria to return to log-phase growth. Five tubes were randomly selected for processing (0 hours). These
112 samples were then processed for colony forming-unit (CFU) enumeration and regrowth (same tube used
113 for both operations). Following regrowth, bacterial samples were scraped and processed for Tn-seq.
114 Regrowth is required before Tn-seq library preparation in order to remove the contribution of DNA to the
115 sequencing library from dead transposon mutants. After collection of enumeration and regrowth samples
116 at 0 hours, antibiotics (or DMSO vehicle as control) were then added to all tubes. Samples were collected
117 at 12 and 48 hours after antibiotic exposure in triplicate and processed for CFU enumeration and regrowth
118 in the same manner as the 0 hours samples.

119

120 **Sample processing for CFU enumeration and regrowth**

121 The bacterial density (CFU/mL) was estimated by removing 400 μ L of bacterial culture,
122 centrifuging (2000 g for 5 minutes) and washing twice with PBS-Tw to remove antibiotic. Washed
123 samples were diluted 10-fold and 50 μ L of each dilution was plated on 7H11 agar without malachite
124 green. Malachite green, which is typically present in standard 7H10 and 7H11 agar formulations, was
125 excluded to avoid potential issues with post-antibiotic recovery in mycobacteria (37). T-shaped spreaders
126 were used to spread liquid evenly across agar plates. CFU were counted after 7-8 days.

127 For regrowth, the remainder of each tube (after removing samples for CFU enumeration) was
128 centrifuged twice and washed (2000 g for 10 min) with 10 mL of PBS-Tw to remove antibiotic. The
129 samples were centrifuged once more and the bacterial pellet was resuspended in 250 μ L PBS-Tw. Fifty
130 μ L of the washed transposon pool was plated on each of four 7H11 agar plates and spread with 10-15 3-
131 mm sterile glass beads to ensure even distribution of liquid across the plate. Samples were regrown for 7-

132 8 days. Bacterial lawns from the four agar plates were scraped and pooled into 2-mL tubes. DNA was
133 extracted from regrown samples, as described previously (short-read sequencing protocol) (38). DNA was
134 processed for Tn-Seq, as described previously (35). Libraries were sequenced (2×75bp) on an Illumina
135 HiSeq 2500 by the Johns Hopkins GRCF High Throughput Sequencing Center. A total of 59 samples (5
136 input-pool samples and 18 groups of output-pool triplicates) were sequenced, yielding between 2,333,295
137 – 7,193,522 reads per sample for a total of 269,324,560 paired-end reads.

138

139 **Antibiotic selection**

140 Doses were selected to reflect antibiotic concentrations at the most common site of infection in
141 non-compromised patients (the lungs) following standard antibiotic dosing. Based on a search of the
142 pharmacokinetic literature, maximum achievable doses in lung tissues were taken to be 54 µg/mL for
143 CLR (39), 0.63 µg/mL for RFB (40), 10.0 µg/mL for MOX (41), and 21.0 µg/mL for EMB (42) (based on
144 non-human primate data). For each drug, a 10-fold dilution series of the estimated maximum achievable
145 dose was performed to explore the impact of dose. A preliminary calibration experiment was performed
146 to estimate the bacterial viability at different antibiotic concentrations (data not shown) and to select the
147 number of concentrations to include (4 total concentrations for CLR, 3 concentrations for the other
148 antibiotics in addition to drug-free controls).

149

150 **Sample selection for sequencing from susceptibility screen**

151 Given resource constraints, only a subset of samples from the differential susceptibility screen was
152 chosen for Tn-seq library prep and sequencing. Samples were sequenced at two manually chosen
153 concentrations for each drug at both available timepoints (12 hrs, 48 hrs). To help identify which should
154 be processed further, objective criteria were established a priori, with the goal of clearly identifying
155 mutants with higher susceptibility to antibiotics, but also reducing the likelihood that mutants were

156 removed by chance due to low bacterial viability during antibiotic exposure. We considered the following
157 3 criteria for selecting samples:

158 (A) Bacterial numbers must exceed 10^6 CFU/mL at all times during exposure. This ensures that the
159 probability of losing a non-defective mutant is minimized, given the 60,129 possible thymine-
160 adenine (TA) sites for the *Himar1* transposon to insert across the MAC109 genome. Only CFU
161 data were used, and we did not attempt to directly estimate the total number of bacterial cells,
162 which can differ significantly from CFU.

163 (B) There should be decreased bacterial viability after antibiotic exposure relative to drug-free
164 controls (as measured by CFU). This ensures the concentration of antibiotic is high enough to
165 have bactericidal activity. Otherwise, the antibiotic concentration might be too low to select for or
166 against mutants with growth phenotypes.

167 (C) Drug concentrations near or below achievable serum concentrations of the drug after standard
168 dosing are preferred. We assumed approximate serum values of 2.31 $\mu\text{g/mL}$ for CLR, 4.42 $\mu\text{g/mL}$
169 for MOX, 0.52 $\mu\text{g/mL}$ RFB and 2.27 $\mu\text{g/mL}$ for EMB (43). In our view, this criterion makes the
170 results more clinically relevant.

171

172 **Identification of hypersusceptible mutants from sequencing data**

173 A schematic of the pipeline to process the data is provided in Figure S1. Raw reads were mapped
174 using the TRANSIT preprocessor (tpp) (44). Counts from tpp were then processed with a custom python
175 script to produce a *.csv file to be read by pandas (version 0.24.1) used for downstream analyses.

176

177 **Effect size/log-fold change calculation**

178 For calculation of the normalized read counts for each mutant, a pseudocount of 4 was added to
179 the raw count from all samples (for stabilization) before dividing read counts by total read count:

$$\tilde{x}_{t,ir} = \frac{X_{t,ir} + \alpha}{\sum_t^T (X_{t,ir} + \alpha)}$$

180
181 (where $x_{t,ir}$ is the normalized read count, $X_{t,ir}$ is the raw read count for transposon insertion site t , for
182 antibiotic treatment group i , for replicate r . α is the pseudocount ($\alpha = 4$) and T is the number of transposon
183 insertion sites). This pseudocount was determined by manual examination of read counts in genes known
184 to be essential and set to be substantially larger than occasional background reads. The normalized read
185 counts were then averaged over samples:

$$\mu_{t,i} = \frac{1}{n_i} \sum_r^{n_i} \tilde{x}_{t,ir}$$

186
187 (where $\mu_{t,i}$ is the average representation of each mutant across samples, and n_i is the number of replicates
188 for treatment group i). An aggregate log-fold-change (LFC) was used as a measure of effect size for
189 differentially susceptible mutants. The aggregate LFC between treatment groups i and j was calculated as
190 the median of the log-fold change change at individual transposon insertion sites within a gene:

$$\text{LFC}_{g,(i/j)} = \text{med}_{t \in G_g} \left(\log_2 \left(\frac{\mu_{t,i}}{\mu_{t,j}} \right) \right)$$

191
192 where G_g is the set of transposon insertion sites annotated to belong to gene g and $\text{LFC}_{g,(i/j)}$ is the log-fold
193 change between treatment groups i and j for gene g . Although this formula is generally useful for
194 comparing any pair of groups, for the work presented here, i always represents a drug-containing
195 treatment group and j always represents the matching drug-free group at the same time point
196

197 **P-value calculation**

198 For calculation of p-values, read counts for each sample were first normalized by dividing by the
199 total read count in each sample (pseudocounts are unnecessary for the non-parametric test described
200 below, and thus not used).

$$x_{t,ir} = \frac{X_{t,ir}}{\sum_t X_{t,ir}}$$

201
202 The Jonckheere-Terpstra (JT) test was then applied to the normalized read counts at each time
203 point (45,46). Briefly, the JT test is a non-parametric test of trend, which is more powerful than the more
204 commonly used Kruskal-Wallis test when the alternative hypothesis assumes a monotonic trend of the
205 treatment groups. In this case, we have three treatment groups for each drug at each time point: No drug,
206 low dose, high dose. We postulated that if a mutant is hypersusceptible at a low dose of antibiotic, it will
207 be even more hypersusceptible at a higher dose of that antibiotic. We define the alternative hypothesis as:

$$H_A : \theta_1 \leq \theta_2 \leq \dots \leq \theta_K$$

208
209 against a null hypothesis:

$$H_0 : \theta_1 = \theta_2 = \dots = \theta_K$$

210
211 (where $\theta_1 \dots \theta_K$ are measures of a centrality parameter and K is the number of treatment groups for the drug
212 at a particular time point (in this case $K = 3$ for each drug)). The JT test statistic (B_t) at site t is defined as:

$$B_t = \sum_{i=1}^{K-1} \sum_{j=i+1}^K \sum_{r=1}^{n_t} \sum_{s=1}^{n_j} \mathbf{1}[x_{t,ir} < x_{t,js}]$$

213
214 (where $\mathbf{1}[\]$ is the indicator function). P-values at individual sites are computed via permutation test.

215 Naively, this would result in non-uniformly distributed p-values due to the discrete nature of the
216 distribution. To ensure a truly uniform distribution, we performed a small correction on the permutation
217 test p-values by sampling from a uniform distribution bounded between adjacent values of the discrete
218 permutation distribution. This process gives precisely uniform p-values under the null hypothesis.

219 Pooling the p-values within each gene (one p-value calculated for each transposon insertion site)
220 is then accomplished with the two-sided Stouffer's method. Finally, adjusted p-values are then computed
221 using the Benjamini-Hochberg procedure.

222

223 **Thresholds for defining differentially susceptible mutants**

224 Gene mutants are considered “differentially susceptible” to a drug if the absolute value of the
225 LFC at the high dose of each drug (relative to no drug control) is greater than 0.5 and the adjusted p-value
226 is less than 0.05. This condition must be met at both the 12 hours and 48 hours time points in order for the
227 mutant to be defined as differentially susceptible to the drug. Mutants with negative LFC are predicted to
228 be hypersusceptible to the drug, while positive LFC indicates the mutant is hypertolerant.

229

230 **Raw data and code availability**

231 The raw sequencing data (*.fastq) from this project can be found in the NCBI Sequence Read
232 Archive (SRA) under BioProject number PRJNA559896. A Jupyter notebook and associated scripts to
233 reproduce the data analysis (including figures) from the raw data is provided on github.com
234 (<https://doi.org/10.5281/zenodo.4542412>).

235

236 **Results**

237 **Effects of antibiotics on bacterial growth at the population level**

238 To monitor the effects of individual antibiotics on the entire bacterial population, we measured
239 CFU and OD₆₀₀ during antibiotic exposure. CFU values obtained following antibiotic exposure for 0, 12,
240 and 48 hrs are provided in Figure S2. OD₆₀₀ values are provided in Figure S3. The same no-drug (vehicle)
241 control data appear in all four plots (performed in triplicate). Notably, the no-drug control curve has an
242 inflection at the 12-hr time point. Truly logarithmic growth should appear as a straight line on this plot.
243 Light microscopy of unstained samples of the no-drug control cultures revealed clumps of approximately
244 5 bacteria (data not shown), likely accounting for the inflection point. Bacterial clumping was likely also
245 present in the antibiotic-containing tubes, although these were not specifically examined. The presence of
246 clumping is unlikely to impact the results of the screen, as there is no reason to suspect that individual
247 transposon mutants were disproportionately distributed among the clumps. Applying the set of criteria for

248 selecting samples for processing, we prepared libraries and sequenced both time points at the following
249 concentrations: CLR 0.54 and 5.4 $\mu\text{g}/\text{mL}$, MOX 0.1 and 1.0 $\mu\text{g}/\text{mL}$, RFB 0.063 and 0.63 $\mu\text{g}/\text{mL}$, EMB
250 2.1 and 0.21 $\mu\text{g}/\text{mL}$. The colored arrows in Figures S1 and S2 indicate the time points sequenced.

251

252 **Identification of mutants with altered antibiotic susceptibility**

253 A total of 161 mutants showed increased susceptibility and 32 mutants showed reduced
254 susceptibility to at least one of the four antibiotics. 46 mutants were hypersusceptible and 14 mutants
255 were hypertolerant to CLR. 6 mutants were found to be hypersusceptible to EMB, while no mutants were
256 hypertolerant to this antibiotic. The MOX screen revealed 103 hypersusceptible and 2 hypertolerant
257 mutants. 84 mutants were found to be hypersusceptible and 108 mutants were hypertolerant to RFB.
258 Effect sizes (after 48 hours of exposure) for mutants with significantly altered antibiotic susceptibility are
259 plotted in Figure 2 and summary data are provided in Tables S3-S6.

260 We also looked for overlaps between the different drug classes tested. Our results of this analysis
261 are summarized in Figure 3 and Table S1 (hypersusceptible mutants) and Table S2 (hypertolerant
262 mutants). Mutants hypersusceptible to multiple antibiotics may reflect genes with a role in more general
263 bacterial persistence mechanisms, while mutants hypertolerant to multiple antibiotics may suggest genes
264 promoting antibiotic susceptibility. Notably, no mutant was found to be hypersusceptible to one antibiotic
265 but hypertolerant to another.

266 Two mutants were hypersusceptible to all four antibiotics tested, namely DFS55_00905
267 (annotated as an acyltransferase, homologous to *M. tuberculosis* Rv0111) and DFS55_12730
268 (hypothetical protein, homologous to Rv1836c). 10 mutants were hypersusceptible to CLR, MOX, and
269 RFB, but not to EMB.

270 Two mutants were identified as hypertolerant to CLR, MOX, and RFB (no mutant was
271 hypertolerant to EMB): DFS55_10765 (annotated as a pyruvate kinase, homologous to Rv1617) and

272 DFS55_20040 (DUF1707 domain-containing protein, homologous to Rv0966c). An additional 4 mutants
273 were found to be hypertolerant to RFB and CLR only, but not MOX. These included DFS55_10660
274 (quinolinate synthase, homologous to Rv1594), DFS55_10665 (L-aspartate oxidase, homologous to
275 Rv1595), DFS55_16845 (trigger factor, homologous to Rv2462c), and DFS55_21750 (hypothetical
276 protein, homologous to Rv3489).

277

278 **Discussion**

279 In this work, we utilized a genome-wide transposon mutant pool to screen for *M. avium* mutants
280 with altered susceptibility to various clinically relevant antibiotics. Compared to the other antibiotics,
281 exposure to MOX yielded the highest number of hypersusceptible mutants, highlighting the many
282 potential targets which might synergize with this antibiotic. Also, given the strong effect sizes observed
283 with MOX relative to the other antibiotics tested, MOX synthetic lethality may represent the greatest
284 opportunity for novel treatment-shortening strategies.

285 Transposon insertions in several known virulence genes were found to enhance susceptibility of
286 *M. avium* to multiple antibiotics. For example, mutations in *secA2* (DFS55_12665 or *rv1821*) conferred
287 hypersusceptibility to both CLR and MOX. The Sec export pathway is conserved across bacteria and
288 exports secreted proteins across the cytoplasmic membrane (48). Mycobacteria have two SecA proteins,
289 SecA1 and SecA2 (48). While SecA1 is essential and facilitates the transport of unfolded proteins through
290 the SecYEG channel via its ATPase activity, the mechanism of export in the SecA2 pathway is less well
291 understood (49). SecA2 is required for secretion of *M. tuberculosis* virulence proteins and arresting
292 phagosome maturation by preventing acidification, thereby facilitating *M. tuberculosis* growth within
293 macrophages (50). In particular, the SecA2-secreted phosphatase SapM and the kinase PknG have been
294 identified as effectors with direct roles in preventing phagosome maturation and promoting *M.*
295 *tuberculosis* intracellular survival and replication (51). As CLR inhibits protein synthesis (52) and SecA2
296 disruption impairs secretion of virulence-related proteins, these two alterations which both dysregulate

297 proteostasis may have a synergistic or additive effect, leading to higher antibiotic susceptibility for this
298 mutant. A similar but more indirect mechanism could be proposed for the sensitization of this mutant to
299 MOX, which inhibits DNA gyrase and topoisomerase IV (52). Both of these enzymes are involved in the
300 winding and unwinding of DNA and are necessary for DNA replication and RNA transcription (53,54).
301 MOX-induced reductions in mRNA transcripts may also dysregulate proteostasis in MAC, potentially
302 explaining the similar phenotypes observed with CLR exposure.

303 RecA (DFS55_08530 or Rv2737c), which was found to be required for MAC tolerance to both MOX
304 and RFB, plays a critical role in the mycobacterial DNA damage response, specifically in the repair of
305 double-stranded breaks, as *M. smegmatis* cells lacking RecA are more sensitive to DNA damage (55).
306 Specifically, after RecBCD resects double-stranded breaks, RecA is loaded onto the 3' end of the DNA,
307 helping to mediate a homology search and subsequent strand invasion (55). By inhibiting DNA
308 topoisomerases, MOX promotes DNA damage and triggers a mutagenic SOS response, which can lead to
309 the formation of persister cells (56). RecA activation promotes the self-cleavage of LexA, which is able to
310 downregulate the SOS regulon (57). In turn, this suppression of the SOS regulon decreases persister
311 formation. Chemical inhibition of RecA with suramin in DNA gyrase-depleted cells has been shown to
312 improve killing of *M. tuberculosis* by several anti-TB drugs, including rifampin and EMB (56). RFB, the
313 rifamycin tested in our study, inhibits DNA-dependent RNA polymerase and suppresses RNA synthesis.
314 Previous work showed that a *recA*-deficient *M. tuberculosis* mutant was unable to develop resistance to
315 rifampin, possibly due to inability to generate an SOS response (58). In short, it appears that inhibiting
316 RecA, thereby suppressing the SOS response, could provide a means to decrease persister formation and
317 improve killing of pathogenic mycobacteria, such as *M. tuberculosis* and MAC.

318 Interestingly, we identified two mutants as hypersusceptible to all four antibiotics tested in our
319 study (Figure 3). These included mutants with transposon insertions in DFS55_00905 (annotated as an
320 acyltransferase, homologous to *rv0111*) and DFS55_12730 (hypothetical protein, homologous to
321 *rv1836c*). Mutants in DFS55_00905 displayed particularly robust hypersusceptibility to MOX (effect

322 size: -2.0 at 1 µg/mL and 48-hr exposure) and EMB (effect size: -1.4 at 2.1 µg/mL, 48 hrs, which was the
323 largest effect size we observed with this drug at 48 hrs). Mutants in DFS55_12730 were strongly
324 hypersusceptible to CLR (effect size: -1.6 at 5.4 µg/mL, 48 hrs), MOX (-1.9 at 1.0 µg/mL, 48 hrs), and
325 RFB (-1.5 at 0.63 µg/mL, 48 hrs). Future work should investigate the function of these gene products and
326 their relationship to the pansusceptibility phenotype observed.

327 An additional 10 mutants were found to be hypersusceptible to CLR, MOX, and RFB, but not to
328 EMB. These included mutants in *sigE* (DFS55_18590, *rv1221*) and an alpha-beta hydrolase gene
329 (DFS55_15065, homologous to *rv2224c*, also known as *caeA* or *hip1*). Deficiency of sigma factor E
330 (SigE) has been shown to confer increased susceptibility of *M. tuberculosis* to multiple drugs, including
331 EMB and rifampin, but not to ciprofloxacin (59). These results differ somewhat from the results of our
332 study. Upon closer examination of our results for EMB, we find that this mutant was barely outside our
333 conservative thresholds for defining hypersusceptible mutants. While adjusted p-values at both time
334 points were below cutoff (0.045 and 0.0001, cutoff: 0.05), the corresponding log-fold-changes were
335 barely above our chosen thresholds (-0.47 and -1, cutoff: -0.5). Therefore, it is possible that our stringent
336 cutoffs misclassified this mutant as displaying similar EMB susceptibility as wild type. On the other hand,
337 the discrepancy regarding hypersusceptibility of *sigE*-deficient mycobacteria to fluoroquinolones may be
338 due to differences between the two species (*M. tuberculosis* vs. MAC, which have vastly different growth
339 rates) and/or the experimental designs (resazurin microtiter assay vs. our Tn-seq screen). Additional
340 studies are required to further evaluate the impact of *sigE* deficiency on MAC susceptibility to EMB and
341 fluoroquinolones. Consistent with our data in MAC, *M. tuberculosis* mutants in *caeA/hip1/rv2224c* have
342 been shown to be hypersusceptible to rifamycins (rifampin) and macrolides (erythromycin) (60). Our data
343 suggest that *caeA* deficiency also confers enhanced susceptibility to fluoroquinolones, which might be
344 useful for designing novel therapies for *M. tuberculosis*.

345 We found 2 mutants that displayed hypertolerance to three of the four antibiotics tested (CLR,
346 MOX, RFB): DFS55_10765 (annotated as a pyruvate kinase, *rv1617*) and DFS55_20040 (DUF1707

347 domain-containing protein, *rv0966c*). Interestingly, Rv1617 deficiency is associated with a large growth
348 defect in *M. tuberculosis* (34,35), but the same phenotype is not observed in DFS55_10765- deficient *M.*
349 *avium* (35). This suggests that the metabolic impact of pyruvate kinase deficiency is remarkably different
350 between MAC and *M. tuberculosis*. Pyruvate kinase catalyzes the transfer of a phosphate group from
351 phosphoenolpyruvate to ADP (yielding pyruvate and ATP). Central metabolism may be disrupted in
352 bacteria lacking this enzyme, possibly triggering the stringent response, which has been previously shown
353 to protect bacteria from antibiotic-mediated killing (61,62). Deletion of pyruvate kinase in *M. tuberculosis*
354 causes allosteric inhibition of the TCA cycle through accumulation of phosphoenolpyruvate (63).
355 Disruption of the TCA cycle, especially alternate catabolism through the glyoxylate shunt, has been
356 linked to antibiotic tolerance in multiple bacterial species, including *P. aeruginosa* (64), *S. aureus*
357 (65,66), and *S. epidermis* (67), suggesting that this pathway may be a common mechanism for promoting
358 antibiotic tolerance. In *M. tuberculosis*, downregulation of the malate synthase GlcB, one of the enzymes
359 in the glyoxylate shunt, caused increased susceptibility to both rifampin and to nitrosative and oxidative
360 stresses *in vitro* (68). Deficiency of isocitrate lyase, another glyoxylate shunt enzyme, also led to
361 increased susceptibility of *M. tuberculosis* to antibiotics *in vitro* (69) and decreased survival in activated
362 macrophages and mice (27). Thus, mycobacterial metabolism, and the TCA cycle in particular, clearly
363 plays an important role in the development of antibiotic tolerance, although more work is necessary to
364 fully elucidate its contributions. DFS55_20040 appears to lack an annotated function in the literature.
365 Additional work is needed to understand the function of these two genes and determine their relationship
366 to antibiotic tolerance in mycobacteria.

367 Our approach has several limitations. First, mutants in essential genes (or those without TA
368 insertion sites) could not be screened, as these could not be recovered with our regrowth techniques.
369 Therefore, we are unable to assess the potential role in antibiotic tolerance of genes essential for growth
370 of *M. avium* in nutrient-rich medium. Second, gene disruptions leading to changes in secreted factors
371 (e.g., extracellular proteins) may be missed by our screen, as these factors may be complemented by

372 factors produced by non-defective mutants present in the same culture. Lastly, we chose a conservative
373 statistical approach (JT-test) and conservative thresholds for p-values and LFCs, which must be met at
374 two different time points. It is likely that mutants with low numbers of insertion sites or somewhat weaker
375 effect sizes were missed.

376 Previous studies have examined mycobacterial antibiotic hypersusceptibility in the context of
377 very low antibiotic concentrations (36). In such an experimental setup, the entire bacterial population
378 continues to grow during antibiotic exposure and libraries were generated directly from bacterial cultures.
379 In contrast, our approach here uses an additional regrowth step on solid agar after antibiotic exposure.
380 This regrowth step produces sufficient material for library generation independent of whether the
381 aggregate bacterial population is growing, stable, or dying. Therefore, our approach is more generally
382 applicable to clinical scenarios in which higher doses of antibiotics may be used, entirely inhibiting
383 aggregate mycobacterial growth.

384 Mutations causing defects while the aggregate population declines or is static are interpreted in
385 our screen as amplifying the killing effect of the antibiotic (given that the wildtype organisms can be
386 assumed to be non-growing). However, an observation of hypersusceptibility in the context of aggregate
387 growth is more difficult to precisely resolve. Thus, it could be that the mutant is killed in the presence of
388 antibiotic, whereas the wild type is able to grow, or it is possible that the mutant is more inhibited by the
389 antibiotic relative to wild type, but continues to grow, albeit at a slower rate. In particular, the overall
390 population declined in the presence of 5.4 $\mu\text{g/mL}$ CLR, suggesting that any defective mutants are killed
391 more rapidly than the wild type. However, at CLR 0.54 $\mu\text{g/mL}$, the overall population increased,
392 suggesting that defective mutants could either be killed more rapidly or merely that their growth is
393 inhibited to a greater extent than that of wild type (see Figure S2). Follow-up studies are needed in order
394 to resolve the behavior of hypersusceptible mutants at this dose.

395 Our study represents a first step towards the development of novel, treatment-shortening
396 strategies for MAC infections through identification of genes affecting antibiotic susceptibility.

397 Biochemical characterizaation of the corresponding gene products might yield novel insights into the
398 mechanisms of MAC antibiotic tolerance and lay the groundwork for the development of novel
399 antibiotics, which might synergize with currently available drugs to more effectively kill tolerant
400 organisms and shorten curative treatment for MAC infections. Future work is needed to validate the
401 susceptibility phenotypes of individual gene-deficient mutants and their respective complemented strains
402 in axenic culture. Proof-of-concept studies could then be performed to demonstrate the treatment-
403 shortening potential of candidate targets in a relevant animal model of pulmonary MAC disease (70,71).
404

405 **Acknowledgements**

406 This publication was made possible by a pilot research grant from the Sherrilyn and Ken Fisher Center for
407 Environmental Infectious Diseases, Division of Infectious Diseases of the Johns Hopkins University
408 School of Medicine. Its contents are solely the responsibility of the authors and do not necessarily
409 represent the official view of the Fisher Center or Johns Hopkins University School of Medicine.

410

411 **Competing Interests Statement:**

412 WMM, HP, CD, LH and PCK have no competing interests. JSB is a founder, director, and equity holder
413 of Neochromosome, Inc. Neochromosome is developing a yeast synthetic biology platform for pathway-
414 level antimicrobial screens.

415

416

417 **References:**

- 418 1. Falkinham JO. Epidemiology of infection by nontuberculous mycobacteria. *Clin Microbiol Rev.*
419 1996 Apr;9(2):177–215.
- 420 2. Wolinsky E. Nontuberculous mycobacteria and associated diseases. *Am Rev Respir Dis.* 1979
421 Jan;119(1):107–59.
- 422 3. Inderlied CB, Kemper CA, Bermudez LE. The *Mycobacterium avium* complex. *Clin Microbiol*
423 *Rev.* 1993 Jul;6(3):266–310.
- 424 4. Ito Y, Hirai T, Maekawa K, Fujita K, Imai S, Tatsumi S, et al. Predictors of 5-year mortality in
425 pulmonary *Mycobacterium avium*-intracellulare complex disease. *Int J Tuberc Lung Dis.*
426 2012;16(3):408–14.
- 427 5. Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, et al. Nontuberculous
428 mycobacterial lung disease prevalence at four integrated health care delivery systems. *Am J Respir*
429 *Crit Care Med.* 2010 Oct 1;182(7):970–6.
- 430 6. Spaulding AB, Lai YL, Zelazny AM, Olivier KN, Kadri SS, Prevots DR, et al. Geographic
431 Distribution of Nontuberculous Mycobacterial Species Identified among Clinical Isolates in the
432 United States, 2009–2013. *Ann Am Thorac Soc.* 2017 Nov;14(11):1655–61.
- 433 7. Henkle E, Hedberg K, Schafer S, Novosad S, Winthrop KL. Population-based Incidence of
434 Pulmonary Nontuberculous Mycobacterial Disease in Oregon 2007 to 2012. *Ann Am Thorac Soc.*
435 2015 May;12(5):642–7.
- 436 8. Winthrop KL, Marras TK, Adjemian J, Zhang H, Wang P, Zhang Q. Incidence and Prevalence of
437 Nontuberculous Mycobacterial Lung Disease in a Large U.S. Managed Care Health Plan, 2008-
438 2015. *Ann Am Thorac Soc.* 2020;17(2):178–85.
- 439 9. Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, et al. The geographic
440 diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET
441 collaborative study. *Eur Respir J.* 2013 Dec;42(6):1604–13.
- 442 10. Griffith DE, Adjemian J, Brown-Elliott BA, Philley JV, Prevots DR, Gaston C, et al.
443 Semiquantitative Culture Analysis during Therapy for *Mycobacterium avium* Complex Lung
444 Disease. *Am J Respir Crit Care Med.* 2015 Sep 15;192(6):754–60.
- 445 11. Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, et al. Treatment of
446 Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical
447 Practice Guideline. *Clin Infect Dis.* 2020 Aug 14;71(4):905–13.
- 448 12. Griffith DE. Therapy of nontuberculous mycobacterial disease. *Curr Opin Infect Dis.* 2007
449 Apr;20(2):198–203.
- 450 13. Parker H, Lorenc R, Ruelas Castillo J, Karakousis PC. Mechanisms of Antibiotic Tolerance in
451 *Mycobacterium avium* Complex: Lessons From Related Mycobacteria. *Front Microbiol.*
452 2020;11:573983.

- 453 14. Tomasz A, Albino A, Zanati E. Multiple antibiotic resistance in a bacterium with suppressed
454 autolytic system. *Nature*. 1970 Jul 11;227(5254):138–40.
- 455 15. Liao J, Sauer K. The MerR-like transcriptional regulator BrIR contributes to *Pseudomonas*
456 *aeruginosa* biofilm tolerance. *J Bacteriol*. 2012 Sep;194(18):4823–36.
- 457 16. Sadvovskaya I, Vinogradov E, Li J, Hachani A, Kowalska K, Filloux A. High-level antibiotic
458 resistance in *Pseudomonas aeruginosa* biofilm: the ndvB gene is involved in the production of
459 highly glycerol-phosphorylated beta-(1->3)-glucans, which bind aminoglycosides. *Glycobiology*.
460 2010 Jul;20(7):895–904.
- 461 17. Thayil SM, Morrison N, Schechter N, Rubin H, Karakousis PC. The role of the novel
462 exopolyphosphatase MT0516 in *Mycobacterium tuberculosis* drug tolerance and persistence. *PLoS*
463 *ONE*. 2011;6(11):e28076.
- 464 18. Boutte CC, Crosson S. Bacterial lifestyle shapes stringent response activation. *Trends Microbiol*.
465 2013 Apr;21(4):174–80.
- 466 19. Chuang Y-M, Belchis DA, Karakousis PC. The polyphosphate kinase gene ppk2 is required for
467 *Mycobacterium tuberculosis* inorganic polyphosphate regulation and virulence. *MBio*. 2013 May
468 21;4(3):e00039-00013.
- 469 20. Chuang Y-M, Bandyopadhyay N, Rifat D, Rubin H, Bader JS, Karakousis PC. Deficiency of the
470 novel exopolyphosphatase Rv1026/PPX2 leads to metabolic downshift and altered cell wall
471 permeability in *Mycobacterium tuberculosis*. *mBio*. 2015 Mar 17;6(2):e02428.
- 472 21. Rodrigues L, Sampaio D, Couto I, Machado D, Kern WV, Amaral L, et al. The role of efflux pumps
473 in macrolide resistance in *Mycobacterium avium* complex. *Int J Antimicrob Agents*. 2009
474 Dec;34(6):529–33.
- 475 22. Rodrigues L, Machado D, Couto I, Amaral L, Viveiros M. Contribution of efflux activity to
476 isoniazid resistance in the *Mycobacterium tuberculosis* complex. *Infect Genet Evol*. 2012
477 Jun;12(4):695–700.
- 478 23. Gupta AK, Katoch VM, Chauhan DS, Sharma R, Singh M, Venkatesan K, et al. Microarray analysis
479 of efflux pump genes in multidrug-resistant *Mycobacterium tuberculosis* during stress induced by
480 common anti-tuberculous drugs. *Microb Drug Resist*. 2010 Mar;16(1):21–8.
- 481 24. Rojony R, Martin M, Campeau A, Wozniak JM, Gonzalez DJ, Jaiswal P, et al. Quantitative analysis
482 of *Mycobacterium avium* subsp. *hominissuis* proteome in response to antibiotics and during
483 exposure to different environmental conditions. *Clin Proteomics*. 2019;16:39.
- 484 25. Archuleta RJ, Yvonne Hoppes P, Primm TP. *Mycobacterium avium* enters a state of metabolic
485 dormancy in response to starvation. *Tuberculosis (Edinb)*. 2005 May;85(3):147–58.
- 486 26. Sangari FJ, Parker A, Bermudez LE. *Mycobacterium avium* interaction with macrophages and
487 intestinal epithelial cells. *Front Biosci*. 1999 Jul 15;4:D582-588.
- 488 27. McKinney JD, Höner zu Bentrup K, Muñoz-Elías EJ, Miczak A, Chen B, Chan WT, et al.
489 Persistence of *Mycobacterium tuberculosis* in macrophages and mice requires the glyoxylate shunt
490 enzyme isocitrate lyase. *Nature*. 2000 Aug 17;406(6797):735–8.


- 491 28. Wayne LG, Hayes LG. An in vitro model for sequential study of shutdown of *Mycobacterium*
492 tuberculosis through two stages of nonreplicating persistence. *Infect Immun*. 1996 Jun;64(6):2062–
493 9.
- 494 29. Wayne LG, Lin KY. Glyoxylate metabolism and adaptation of *Mycobacterium tuberculosis* to
495 survival under anaerobic conditions. *Infect Immun*. 1982 Sep;37(3):1042–9.
- 496 30. van Opijnen T, Bodi KL, Camilli A. Tn-seq: high-throughput parallel sequencing for fitness and
497 genetic interaction studies in microorganisms. *Nat Methods*. 2009 Oct;6(10):767–72.
- 498 31. Langridge GC, Phan M-D, Turner DJ, Perkins TT, Parts L, Haase J, et al. Simultaneous assay of
499 every *Salmonella Typhi* gene using one million transposon mutants. *Genome Res*. 2009
500 Dec;19(12):2308–16.
- 501 32. Goodman AL, McNulty NP, Zhao Y, Leip D, Mitra RD, Lozupone CA, et al. Identifying genetic
502 determinants needed to establish a human gut symbiont in its habitat. *Cell Host Microbe*. 2009 Sep
503 17;6(3):279–89.
- 504 33. Gawronski JD, Wong SMS, Giannoukos G, Ward DV, Akerley BJ. Tracking insertion mutants
505 within libraries by deep sequencing and a genome-wide screen for *Haemophilus* genes required in
506 the lung. *Proc Natl Acad Sci U S A*. 2009 Sep 22;106(38):16422–7.
- 507 34. DeJesus MA, Gerrick ER, Xu W, Park SW, Long JE, Boutte CC, et al. Comprehensive Essentiality
508 Analysis of the *Mycobacterium tuberculosis* Genome via Saturating Transposon Mutagenesis.
509 *MBio*. 2017 Jan 17;8(1).
- 510 35. Matern WM, Jenquin RL, Bader JS, Karakousis PC. Identifying the essential genes of
511 *Mycobacterium avium* subsp. *hominissuis* with Tn-Seq using a rank-based filter procedure.
512 *Scientific Reports*. 2020 Dec;10(1):1095.
- 513 36. Xu W, DeJesus MA, Rücker N, Engelhart CA, Wright MG, Healy C, et al. Chemical genomic
514 interaction profiling reveals determinants of intrinsic antibiotic resistance in *Mycobacterium*
515 tuberculosis. *Antimicrob Agents Chemother*. 2017 Sep 11;
- 516 37. Gelman E, McKinney JD, Dhar N. Malachite green interferes with postantibiotic recovery of
517 mycobacteria. *Antimicrob Agents Chemother*. 2012 Jul;56(7):3610–4.
- 518 38. Matern WM, Bader JS, Karakousis PC. Genome analysis of *Mycobacterium avium* subspecies
519 *hominissuis* strain 109. *Sci Data*. 2018 Dec 4;5:180277.
- 520 39. Fish DN, Gotfried MH, Danziger LH, Rodvold KA. Penetration of clarithromycin into lung tissues
521 from patients undergoing lung resection. *Antimicrob Agents Chemother*. 1994 Apr;38(4):876–8.
- 522 40. Blaschke TF, Skinner MH. The clinical pharmacokinetics of rifabutin. *Clin Infect Dis*. 1996 Apr;22
523 Suppl 1:S15-21; discussion S21-22.
- 524 41. Prideaux B, Via LE, Zimmerman MD, Eum S, Sarathy J, O'Brien P, et al. The association between
525 sterilizing activity and drug distribution into tuberculosis lesions. *Nat Med*. 2015 Oct;21(10):1223–
526 7.

- 527 42. Liss RH, Letourneau RJ, Schepis JP. Distribution of ethambutol in primate tissues and cells. *Am*
528 *Rev Respir Dis*. 1981 May;123(5):529–32.
- 529 43. van Ingen J, Egelund EF, Levin A, Totten SE, Boeree MJ, Mouton JW, et al. The pharmacokinetics
530 and pharmacodynamics of pulmonary *Mycobacterium avium* complex disease treatment. *Am J*
531 *Respir Crit Care Med*. 2012 Sep 15;186(6):559–65.
- 532 44. DeJesus MA, Ambadipudi C, Baker R, Sasseti C, Ioerger TR. TRANSIT--A Software Tool for
533 Himar1 TnSeq Analysis. *PLoS Comput Biol*. 2015 Oct;11(10):e1004401.
- 534 45. Jonckheere AR. A Distribution-Free k-Sample Test Against Ordered Alternatives. *Biometrika*. 1954
535 Jun;41(1/2):133.
- 536 46. Terpstra, T.J. The Asymptotic Normality and Consistency of Kendall's Test against Trend, When
537 Ties Are Present in One Ranking. *Indag Math*. 1952;14(3):327–33.
- 538 47. Matern W. wmatern/hypersusceptibility_MAC109: Release with DOI (zenodo) [Internet]. Zenodo;
539 2021 [cited 2021 Feb 15]. Available from: <https://zenodo.org/record/4542412>
- 540 48. Braunstein M, Brown AM, Kurtz S, Jacobs WR. Two nonredundant SecA homologues function in
541 mycobacteria. *J Bacteriol*. 2001 Dec;183(24):6979–90.
- 542 49. Ligon LS, Rigel NW, Romanchuk A, Jones CD, Braunstein M. Suppressor analysis reveals a role
543 for secY in the secA2-dependent protein export pathway of mycobacteria. *Journal of Bacteriology*.
544 2013;195(19):4456–65.
- 545 50. Sullivan JT, Young EF, Mccann JR, Braunstein M. The *Mycobacterium tuberculosis* SecA2 system
546 subverts phagosome maturation to promote growth in macrophages. *Infection and Immunity*. 2012
547 Mar;80(3):996–1006.
- 548 51. Zulauf KE, Sullivan JT, Braunstein M. The SecA2 pathway of *Mycobacterium tuberculosis* exports
549 effectors that work in concert to arrest phagosome and autophagosome maturation. *PLoS Pathogens*.
550 2018 Apr 1;14(4).
- 551 52. Karakousis PC. Mechanisms of Action and Resistance of Antimycobacterial Agents. In: Mayers
552 DL, editor. *Antimicrobial Drug Resistance* [Internet]. Totowa, NJ: Humana Press; 2009 [cited 2021
553 Feb 8]. p. 271–91. Available from: http://link.springer.com/10.1007/978-1-59745-180-2_24
- 554 53. Dorman CJ. DNA supercoiling and transcription in bacteria: a two-way street. *BMC Mol Cell Biol*.
555 2019 Jul 18;20(1):26.
- 556 54. Pham TDM, Ziora ZM, Blaskovich MAT. Quinolone antibiotics. *Medchemcomm*. 2019 Oct
557 1;10(10):1719–39.
- 558 55. Gupta R, Barkan D, Redelman-Sidi G, Shuman S, Glickman MS. Mycobacteria exploit three
559 genetically distinct DNA double-strand break repair pathways. *Molecular Microbiology*. 2011
560 Jan;79(2):316–30.
- 561 56. Choudhary E, Sharma R, Kumar Y, Agarwal N. Conditional silencing by CRISPRi reveals the role
562 of DNA gyrase in formation of drug-tolerant persister population in *Mycobacterium tuberculosis*.
563 *Frontiers in Cellular and Infection Microbiology*. 2019;9(MAR):70.

- 564 57. Malik M, Chavda K, Zhao X, Shah N, Hussain S, Kurepina N, et al. Induction of mycobacterial
565 resistance to quinolone class antimicrobials. *Antimicrobial Agents and Chemotherapy*. 2012
566 Jul;56(7):3879–87.
- 567 58. Wipperman MF, Heaton BE, Nautiyal A, Adefisayo O, Evans H, Gupta R, et al. Mycobacterial
568 Mutagenesis and Drug Resistance Are Controlled by Phosphorylation- and Cardiolipin-Mediated
569 Inhibition of the RecA Coprotease. *Molecular Cell*. 2018 Oct 4;72(1):152-161.e7.
- 570 59. Pisu D, Provvedi R, Espinosa DM, Payan JB, Boldrin F, Palù G, et al. The Alternative Sigma
571 Factors SigE and SigB Are Involved in Tolerance and Persistence to Antitubercular Drugs.
572 *Antimicrobial Agents and Chemotherapy*. 2017 Dec;61(12):e01596-17, e01596-17.
- 573 60. Vandal OH, Roberts JA, Odaira T, Schnappinger D, Nathan CF, Ehrt S. Acid-susceptible mutants of
574 *Mycobacterium tuberculosis* share hypersusceptibility to cell wall and oxidative stress and to the
575 host environment. *J Bacteriol*. 2009 Jan;191(2):625–31.
- 576 61. Nguyen D, Joshi-Datar A, Lepine F, Bauerle E, Olakanmi O, Beer K, et al. Active Starvation
577 Responses Mediate Antibiotic Tolerance in Biofilms and Nutrient-Limited Bacteria. *Science*. 2011
578 Nov 18;334(6058):982–6.
- 579 62. Dutta NK, Klinkenberg LG, Vazquez M-J, Segura-Carro D, Colmenarejo G, Ramon F, et al.
580 Inhibiting the stringent response blocks *Mycobacterium tuberculosis* entry into quiescence and
581 reduces persistence. *Sci Adv*. 2019 Mar;5(3):eaav2104.
- 582 63. Ehrt S, Schnappinger D, Rhee KY. Metabolic principles of persistence and pathogenicity in
583 *Mycobacterium tuberculosis*. *Nat Rev Microbiol*. 2018 Aug;16(8):496–507.
- 584 64. Meylan S, Porter CBM, Yang JH, Belenky P, Gutierrez A, Lobritz MA, et al. Carbon Sources Tune
585 Antibiotic Susceptibility in *Pseudomonas aeruginosa* via Tricarboxylic Acid Cycle Control. *Cell*
586 *Chem Biol*. 2017 Feb 16;24(2):195–206.
- 587 65. Zalis EA, Nuxoll AS, Manuse S, Clair G, Radlinski LC, Conlon BP, et al. Stochastic Variation in
588 Expression of the Tricarboxylic Acid Cycle Produces Persister Cells. *mBio*. 2019 Sep 17;10(5).
- 589 66. Rowe SE, Wagner NJ, Li L, Beam JE, Wilkinson AD, Radlinski LC, et al. Reactive oxygen species
590 induce antibiotic tolerance during systemic *Staphylococcus aureus* infection. *Nat Microbiol*. 2020
591 Feb;5(2):282–90.
- 592 67. Thomas VC, Chittezhham Thomas V, Kinkead LC, Janssen A, Schaeffer CR, Woods KM, et al. A
593 dysfunctional tricarboxylic acid cycle enhances fitness of *Staphylococcus epidermidis* during β -
594 lactam stress. *mBio*. 2013 Aug 20;4(4).
- 595 68. Singh KS, Sharma R, Keshari D, Singh N, Singh SK. Down-regulation of malate synthase in
596 *Mycobacterium tuberculosis* H37Ra leads to reduced stress tolerance, persistence and survival in
597 macrophages. *Tuberculosis*. 2017 Sep;106:73–81.
- 598 69. Nandakumar M, Nathan C, Rhee KY. Isocitrate lyase mediates broad antibiotic tolerance in
599 *Mycobacterium tuberculosis*. *Nat Commun*. 2014 Sep;5(1):4306.

- 600 70. Andréjak C, Almeida DV, Tyagi S, Converse PJ, Ammerman NC, Grosset JH. Characterization of
601 mouse models of Mycobacterium avium complex infection and evaluation of drug combinations.
602 Antimicrob Agents Chemother. 2015 Apr;59(4):2129–35.
- 603 71. Verma D, Stapleton M, Gadwa J, Vongtongsalee K, Schenkel AR, Chan ED, et al. Mycobacterium
604 avium Infection in a C3HeB/FeJ Mouse Model. Front Microbiol. 2019;10:693.
- 605


606 **Figures**



607

608 **Figure 1:** Schematic of transposon mutant screen to identify hypersusceptible mutants following
609 exposure to multiple doses of various antibiotics in liquid culture. After antibiotic exposure, cultures were
610 regrown on solid agar to enrich for surviving bacteria. After regrowth, DNA was extracted and prepared
611 for Tn-seq analysis. Hypersusceptible mutants were identified using a non-parametric statistical approach.


612



613

614 **Figure 2:** Bar chart showing the effect size of each statistically significant mutant. Each bar represents a
615 single gene. A negative value represents a hypersusceptible mutant, while a positive value signifies that a
616 mutant is less susceptible (hypertolerant) to the antibiotic. (A) clarithromycin, (B) ethambutol, (C)
617 moxifloxacin, (D) rifabutin.


618



619

620 **Figure 3:** Venn diagram of identified hypersusceptible (Panel A) and hypertolerant transposon mutants
621 (Panel B). Note that in Panel A the set of ethambutol-hypersusceptible mutants has been partitioned into
622 two sets (both in yellow). Partitioning in this way greatly simplifies the diagram. Gene names in each
623 category can be found in Tables S1-S2.


624



625

626 **Figure S1:** Schematic of the computational pipeline. The raw reads from Tn-seq were input into tpp,
627 outputting a count for each TA position in the MAC109 genome. Counts were then normalized and log-
628 fold changes calculated. A non-parametric test of trend (Jonckheere-Terpstra Test) was used to calculate
629 p-values for each TA site. P-values for TA sites in the same gene were pooled using Stouffer's method.
630 Statistically significant mutants were selected based on the log-fold changes and Benjamini-Hochberg
631 FDR-adjusted p-values. See Methods for additional details of these steps.


632



633

634 **Figure S2:** Bacterial viability of cultures by drug, dose, and time point (3 replicates each). Error bars
635 show the minimum, maximum, and median. The arrows at the bottom indicate time point and doses used
636 for Tn-seq. Drug-free controls (blue) are replotted in each subpanel for reference. All doses and time
637 points were collected for drug-free controls.

638



639

640 **Figure S3:** OD₆₀₀ values by drug, dose, and time point. The arrows at the bottom indicate time point and
641 doses used for Tn-seq. Drug-free controls (blue) are replotted in each subpanel for reference. All doses
642 and time points were used for drug-free controls.

643

644 **Tables**

645 **Table S1:** Summary prediction table for antibiotic hypersusceptible MAC109 mutants.

646

647 **Table S2:** Summary prediction table for antibiotic hypertolerant MAC109 mutants.

648

649 **Tables S3:** Clarithromycin-hypersusceptible and hypertolerant MAC109 transposon mutants by dose and
650 time point.

651

652 **Tables S4:** Moxifloxacin-hypersusceptible and hypertolerant MAC109 transposon mutants by dose and
653 time point.

654

655 **Tables S5:** Rifabutin-hypersusceptible and hypertolerant MAC109 transposon mutants by dose and time
656 point.

657

658 **Tables S6:** Ethambutol-hypersusceptible and hypertolerant MAC109 transposon mutants by dose and
659 time point.

660